Can Ketamine Treat Depression -Exploring The Reality!


Ketamine helps in rapidly reducing suicidal thoughts and getting rid of other symptoms of depression. It is also an effective treatment for people suffering from anxiety and depression.

Ketamine helps to regrow the neuron connections of the brain, which promotes the increase of positive thoughts. Hence, Ketamine is usually referred to as antidepressant medicine. 

The Park Slope Ketamine infusion treatment helps the patient get rid of their suicidal tendency and helps them to live a normal life. 

How does Ketamine treat depression?

It is not yet clear how the drug affects the person and helps cure depression. However, it is found to release an antidepressant effect in patients with some serious depression issues. 

The patients consuming Ketamine are seen as having changes in the NMDA receptors of the brain. Ketamine targets these receptors and binds them together. Hence as a result of this, the amount of glutamine, a neurotransmitter, appears in the spaces between the neurons. 

This neurotransmitter activates the connection between AMPA receptors. As a result, new pathways are created amazon the neurons leading to the lightning of mood and affecting the thought pattern and the behavioral pattern of the brain. This process is known as synaptogenesis

What are the side effects of Ketamine?

Some of the side effects o Ketamine are as follows. 

  • High blood pressure.
  • dissociation
  • Nausea and vomiting.
  • Perceptual disturbances.

When should ketamine be avoided? 

Ketamine should be avoided in the following cases:

  1. People with a history of psychosis or schizophrenia must avoid ketamine as it may worsen the condition. 
  2. Teenagers still in adolescence and have a developing brain must not intake Ketamine. 
  3. A pregnant or a breastfeeding woman. 
  4. People that have a history of substance use disorder or drug addictions. 
  5. Olde-aged adults with the symptoms of dementia. 

Ketamine dose and delivery

Ketamine can be provided to the patient by intravenous drip, injection, or nasal spray.

The mixed results do not provide a clear perception of which method is best when providing patients with these medicines. 

In New South Wales, Ketamine was given to older people through injection. 68.8% of the patients reported improvement in their symptoms and said that they are able to live a better life. 

In another trial, Ketamine was provided to the patients with a nasal spray. Here all the patients suffered from the side effects and could not stay consistent with their treatment. 

This trial was canceled, considering the side effects and no improvements in the patients.